title: Contraception in the context of HIV/AIDS: a review.
abstract: Over 50% of the 33.3 million HIV-positive persons are women within the reproductive age group. With increasing availability and use of highly active antiretroviral therapy (HAART), the prognosis, life expectancy and quality of life of infected persons has improved. HIV-positive women, like their uninfected counterparts, may desire to plan pregnancies, limit their families, or avoid pregnancy. The effective use of contraception by HIV-positive clients can contribute significantly to reduction in both sexual and vertical transmission of the virus. HIV-positive clients can use most of the available contraception methods including barrier, hormonal, intrauterine devices and sterilization. However, some antiretroviral drugs interact with hormonal contraceptives with potentials for reduction in efficacy. Dual protection with concomitant use of a more effective contraceptive method and male or female condom to prevent HIV and Sexually transmitted infections (STIs) is the standard. It is necessary to make provision for contraceptive service as part of comprehensive care for the HIV-positive client.
authors.affiliation: Department of Obstetrics & Gynaecology, National Hospital, Abuja, Nigeria. agboschris@yahoo.com
authors.forename: Chris O
authors.initials: CO
authors.lastname: Agboghoroma
mesh_terms: D000163:Acquired Immunodeficiency Syndrome; D000328:Adult; D000349:Africa; D019380:Anti-HIV Agents / Q000494:pharmacology; D003268:Contraception Behavior; D044363:Contraception, Postcoital; D003271:Contraceptive Agents, Female / Q000494:pharmacology; D003376:Counseling; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000635:transmission; D015438:Health Behavior; D006801:Humans; D007434:Intrauterine Devices; D008297:Male; D011247:Pregnancy; D013089:Spermatocidal Agents
chemical_list: D019380:Anti-HIV Agents; D003271:Contraceptive Agents, Female; D013089:Spermatocidal Agents